C92.0 Acute myeloblastic leukemia

Name of the Condition

• Acute Myeloblastic Leukemia

Summary

Acute myeloblastic leukemia (AML) is a cancer of the bone marrow that results in the rapid growth of abnormal myeloblasts, a type of immature white blood cell. This uncontrolled proliferation disrupts normal blood cell production, leading to deficiencies in red blood cells, platelets, and functional white blood cells. AML is classified as an acute leukemia due to its rapid onset and progression.

Causes

AML arises from genetic mutations in hematopoietic stem cells, which disrupt normal cell differentiation and promote uncontrolled proliferation. These mutations may occur spontaneously or be acquired. Common mutations involve genes such as FLT3, NPM1, and RUNX1, which affect cell growth and survival pathways.

Risk Factors

• Age: Primarily affects older adults, with incidence increasing after age 60.
• Previous chemotherapy or radiation therapy for other cancers.
• Exposure to high levels of benzene or other industrial chemicals.
• Genetic disorders, including Down syndrome and Fanconi anemia.
• Myelodysplastic syndromes or other pre-existing bone marrow diseases.

Symptoms

• Fatigue, weakness, or shortness of breath due to anemia.
• Easy bruising, bleeding, or petechiae from low platelet counts.
• Frequent or severe infections due to neutropenia.
• Unexplained fever or weight loss.
• Bone or joint pain.
• Enlarged spleen or liver (splenomegaly/hepatomegaly).

Diagnosis

Diagnosis requires a combination of blood tests to evaluate cell counts and morphology, followed by a bone marrow biopsy to assess blast cell percentage and genetic abnormalities. Flow cytometry and cytogenetic analysis identify specific mutations (e.g., FLT3, NPM1) to confirm the subtype and guide treatment.

Treatment Options

Treatment is tailored to the patient’s age, overall health, and genetic profile. Options include:

• Induction chemotherapy to achieve remission.
• Consolidation therapy to eliminate residual disease.
• Targeted therapies (e.g., FLT3 inhibitors) for specific mutations.
• Stem cell transplantation for eligible patients.
• Supportive care (e.g., blood transfusions, antibiotics) to manage complications.

Prognosis and Follow-Up

Prognosis varies based on age, genetic markers, and response to initial treatment. Younger patients with favorable genetics often have better outcomes. Follow-up involves regular blood tests, bone marrow assessments, and monitoring for relapse. Long-term survival depends on maintaining remission and managing treatment-related toxicities.

Complications

• Infections due to neutropenia or impaired immune function.
• Bleeding or hemorrhage from thrombocytopenia.
• Anemia leading to fatigue or organ dysfunction.
• Tumor lysis syndrome during aggressive treatment.
• Resistance to chemotherapy or relapse.

Lifestyle & Prevention

• Avoid exposure to known carcinogens like benzene.
• Maintain a balanced diet and regular exercise to support overall health.
• Quit smoking, as it may increase risk.
• Follow recommended cancer screening for high-risk individuals.
• Discuss genetic counseling if a hereditary predisposition is suspected.

When to Seek Professional Help

Seek immediate medical attention for:

• Unexplained fatigue, fever, or weight loss lasting more than a week.
• Persistent bruising, bleeding, or unusual rashes.
• Frequent infections that do not improve with treatment.
• Sudden onset of bone pain or abdominal swelling.

Tips for Medical Coders

• Code C92.0 is specific to acute myeloblastic leukemia without further subclassification.
• Ensure documentation supports the acute nature of the diagnosis (e.g., blast cell percentage, rapid symptom onset).
• Verify that no other leukemia subtypes (e.g., promyelocytic) are documented, as these require distinct codes.
• Include relevant details like genetic markers or treatment response if available, as they may impact coding accuracy.